TABLE 5.
Ongoing clinical trials about some investigational compounds for IPF.
| Targets | Drugs | Clinical trial information |
|---|---|---|
| LPC-ATX-LPA | BMS-986278 (LPA1R antagonist) | Phase 2 (recruiting, NCT04308681) |
| PTX-2/SAP | PRM-151(Intravenous recombinant human pentraxin-2) | Phase 3 (recruiting, NCT04594707, NCT04552899) |
| CTGF/CNN2 | FG-3019/Pamrevlumab (CTGF mAb) | Phase 3 (recruiting, NCT04419558, NCT03955146) |
| Galectin 3 | TD139 (small-molecule antagonist of Galectin-3) | Phase 2 (recruiting, NCT03832946) |
| Oxidative stress | Niacin (nicotinic acid) | Phase 2 (recruiting, NCT0386592) |
| Setanaxib/GKT137831(NOS1/4 inhibitor) | Phase 2 (recruiting, NCT03865927) | |
| JNK | Jaktinib Dihydrochloride Monohydrate (JNK1/2 inhibitor) | Phase 2 (recruiting, NCT04312594) |
| CC-90001 (JNK1/2 inhibitor) | Phase 2 (active, not recruiting, NCT03142191) | |
| Src | Saracatinib (Src kinase inhibitor) | Phase 1/2 (recruiting, NCT04598919) |
| Hedgehog pathways | taladegib/ENV-101(Smo receptor inhibitor) | Phase 2 (not yet recruiting, NCT04968574) |
| Leukotrienes | MN-001/Tipelukast (leukotriene receptor antagonist) | Phase 2(Active, not recruiting, NCT02503657) |
| LOXL2 | EGCG (irreversible inhibitor of both LOXL2 and TGF-β receptors 1 and 2 kinase) | Early Phase 1 (recruiting, NCT03928847) |
| IRE1 | ORIN1001(IRE1 inhibitor) | Phase 1 (recruiting, NCT04643769) |
| PDE4b | BI 1015550(PDE4b inhibitor) | Phase 2 (active, not recruiting, NCT04419506) |
| NDMA | NP-120/Ifenprodil (N-methyl-d-aspartate (NDMA) receptor glutamate receptor antagonist) | Phase 2 (recruiting, NCT04318704) |
| B cell | Ianalumab/VAY736(B-cell activating factor receptor mAb) | Phase 2 (active, not recruiting, NCT03287414) |
| Rituximab (CD20 chimeric mAb) | Phase 2 (active, not recruiting, NCT01969409); Phase 2 (recruiting, NCT03584802); Phase 2 (recruiting, NCT03286556); Phase2 (recruiting, NCT03500731) | |
| Traditional medicine | Jin-shui Huan-xian granule | Not Applicable (recruiting, NCT04187690) |
| Fuzheng Huayu tablet | Phase 2 (recruiting, NCT04279197) |